Futura Medical PLC
14 November 2019
Futura Medical Publishes Fireside Chat with Professor Wayne Hellstrom, member of the Futura Medical KOL Advisory Panel
14 November 2019
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys(R) drug delivery technology currently focused on sexual health and pain, today publishes a fireside chat with Professor Wayne Hellstrom, specialist in diagnosis and treatment of male sexual dysfunction and a member of the Futura Medical Key Opinion Leader ("KOL") Advisory Panel.
This follows Futura's third Scientific Advisory Meeting with high profile US KOLs in the field of erectile dysfunction at the 20(th) Annual Fall Scientific Meeting of Sexual Medicine Society of North America (SMSNA), on 24-27 October 2019 in Nashville, Tennessee USA.
Professor Wayne Hellstrom spoke with Futura Medical's Executive Director and Head of R&D, Ken James on the significant negative effect ED has on the quality of life, relationships and overall wellbeing of ED sufferers and their partners. The informal chat also includes discussion on Futura's lead product MED2005, a topical glyceryl trinitrate ("GTN") gel for the treatment of erectile dysfunction ("ED").
A link to the fireside chat can be found here.
Dr. Wayne J.G. Hellstrom is Professor of Urology and Chief of Andrology at Tulane University School of Medicine in New Orleans, and Past President of the Sexual Medicine Society of North America and the International Society of Sexual Medicine (ISSM).
James Barder, Chief Executive Officer of Futura Medical said: "Futura held its third Advisory Board Panel meeting with leading practitioners in urology and sexual medicine with a US focus at the recent Annual SMSNA scientific meeting in Nashville, and once again were very pleased to have received a positive reaction to the therapeutic potential and differentiation of MED2005, reflecting limited innovation in the past 20 years. As part of Futura's educational programme to build awareness ahead of the Phase 3 results, we are very pleased to share our conversation with prominent KOL Professor Hellstrom, on the significant negative effect ED has on the quality of life, relationships and overall wellbeing of ED sufferers and their partners. I would like to thank Professor Hellstrom for his continued support.
We look forward to the Phase 3 data read out, which has made excellent progress to date and is on track to deliver headline efficacy and safety data in December this year, a key value inflection point for the Company."
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Tel: +44 (0) 1483 685 670
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Tel: +44 (0) 203 950 9144
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys(R) drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension. FM57 is progressing on track, with headline data expected by the end of 2019.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.
(END) Dow Jones Newswires
November 14, 2019 02:01 ET (07:01 GMT)